Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
131 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pruritus - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pruritus - Pipeline Review, H2 2017, provides an overview of the Pruritus (Dermatology) pipeline landscape. Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pruritus - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pruritus (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Pruritus (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 12, 6, 1 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Pruritus (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus (Dermatology). - The pipeline guide reviews pipeline therapeutics for Pruritus (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Pruritus (Dermatology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Pruritus (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Pruritus (Dermatology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Pruritus (Dermatology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Pruritus (Dermatology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents
2 List of Tables 4 List of Figures 4 Introduction 6 Global Markets Direct Report Coverage 6 Pruritus - Overview 7 Pruritus - Therapeutics Development 8 Pipeline Overview 8 Pipeline by Companies 9 Pipeline by Universities/Institutes 12 Products under Development by Companies 13 Products under Development by Universities/Institutes 15 Pruritus - Therapeutics Assessment 16 Assessment by Target 16 Assessment by Mechanism of Action 19 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Pruritus - Companies Involved in Therapeutics Development 26 Albireo Pharma Inc 26 Allergan Plc 26 Amorepacific Corp 27 Asana BioSciences LLC 27 Cara Therapeutics Inc 28 Celgene Corp 28 Chugai Pharmaceutical Co Ltd 29 ELORAC Inc 29 GlaxoSmithKline Plc 30 Hydra Biosciences Inc 30 J Uriach Y Compania SA 31 NeuroCycle Therapeutics GmbH 31 Patagonia Pharmaceuticals LLC 32 Patara Pharma Inc 32 Phosphagenics Ltd 33 RDD Pharma Ltd 33 Sanwa Kagaku Kenkyusho Co Ltd 34 Shionogi & Co Ltd 34 Sienna Biopharmaceuticals Inc 35 Sumitomo Dainippon Pharma Co Ltd 35 Teikoku Pharma USA Inc 36 Tesaro Inc 36 Tioga Pharmaceuticals Inc 37 Toray Industries Inc 37 Vanda Pharmaceuticals Inc 38 Pruritus - Drug Profiles 39 A-4250 - Drug Profile 39 apremilast - Drug Profile 43 asimadoline - Drug Profile 54 ASN-008 - Drug Profile 56 B-244 - Drug Profile 57 cromolyn sodium - Drug Profile 59 difelikefalin - Drug Profile 61 GSK-2330672 - Drug Profile 71 lidocaine hydrochloride - Drug Profile 73 nalbuphine hydrochloride ER - Drug Profile 74 nalfurafine hydrochloride - Drug Profile 77 naloxone hydrochloride - Drug Profile 79 NCT-10004 - Drug Profile 80 nemolizumab - Drug Profile 81 onabotulinumtoxinA - Drug Profile 83 PAC-14028 - Drug Profile 88 PATN-02 - Drug Profile 90 Peptides to Target TRPV1 for Pain and Itch - Drug Profile 91 phenylbutyrate - Drug Profile 92 PR-38 - Drug Profile 93 RDD-1609 - Drug Profile 94 rupatadine - Drug Profile 95 SCH-900978 - Drug Profile 96 serlopitant - Drug Profile 97 SK-1405 - Drug Profile 100 Small Molecule for Pruritus - Drug Profile 101 Small Molecule to Agonize KOR1 for Pruritus - Drug Profile 102 Small Molecules to Agonize CB2 for Pruritus - Drug Profile 103 Small Molecules to Antagonize Mas-Related G-Protein Coupled Receptor for Pruritus - Drug Profile 104 Small Molecules to Antagonize TRPV3 for Pain,Pruritus and Psoriasis - Drug Profile 105 SNA-120 - Drug Profile 106 SNA-125 - Drug Profile 109 TPU-010 - Drug Profile 110 tradipitant - Drug Profile 111 VVZ-149 - Drug Profile 113 Pruritus - Dormant Projects 115 Pruritus - Discontinued Products 117 Pruritus - Product Development Milestones 118 Featured News & Press Releases 118 Appendix 128 Methodology 128 Coverage 128 Secondary Research 128 Primary Research 128 Expert Panel Validation 128 Contact Us 128 Disclaimer 129
List of Tables
Number of Products under Development for Pruritus, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pruritus - Pipeline by Albireo Pharma Inc, H2 2017 Pruritus - Pipeline by Allergan Plc, H2 2017 Pruritus - Pipeline by Amorepacific Corp, H2 2017 Pruritus - Pipeline by Asana BioSciences LLC, H2 2017 Pruritus - Pipeline by Cara Therapeutics Inc, H2 2017 Pruritus - Pipeline by Celgene Corp, H2 2017 Pruritus - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017 Pruritus - Pipeline by ELORAC Inc, H2 2017 Pruritus - Pipeline by GlaxoSmithKline Plc, H2 2017 Pruritus - Pipeline by Hydra Biosciences Inc, H2 2017 Pruritus - Pipeline by J Uriach Y Compania SA, H2 2017 Pruritus - Pipeline by NeuroCycle Therapeutics GmbH, H2 2017 Pruritus - Pipeline by Patagonia Pharmaceuticals LLC, H2 2017 Pruritus - Pipeline by Patara Pharma Inc, H2 2017 Pruritus - Pipeline by Phosphagenics Ltd, H2 2017 Pruritus - Pipeline by RDD Pharma Ltd, H2 2017 Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2017 Pruritus - Pipeline by Shionogi & Co Ltd, H2 2017 Pruritus - Pipeline by Sienna Biopharmaceuticals Inc, H2 2017 Pruritus - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017 Pruritus - Pipeline by Teikoku Pharma USA Inc, H2 2017 Pruritus - Pipeline by Tesaro Inc, H2 2017 Pruritus - Pipeline by Tioga Pharmaceuticals Inc, H2 2017 Pruritus - Pipeline by Toray Industries Inc, H2 2017 Pruritus - Pipeline by Vanda Pharmaceuticals Inc, H2 2017 Pruritus - Dormant Projects, H2 2017 Pruritus - Dormant Projects, H2 2017 (Contd..1), H2 2017 Pruritus - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
